Eli Lilly And Company (LLY), Rigel Pharmaceuticals (RIGL) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The adaptive Phase 2a/2b study titled “An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis” tests a new oral drug in adults with active rheumatoid arthritis. The goal is to see if the medicine can improve symptoms and remain safe enough to justify larger, late-stage trials.
The trial evaluates LY3871801, an oral drug designed to calm the immune activity that drives joint damage in rheumatoid arthritis. Placebo capsules are used as a control group, allowing Lilly and Rigel to compare real drug performance against no active treatment in a clean, simple way.
The study is interventional and randomized, meaning participants are split by chance into different treatment groups. It is double-blind and placebo-controlled, so neither patients nor doctors know who gets LY3871801 versus placebo, and the main aim is to measure treatment benefit and safety.
The trial began enrolling after initial submission on 2023-04-28 and has now reached overall status “Completed,” marking the end of active treatment and follow-up. The latest update on 2026-05-20 signals that data are being cleaned and reviewed, with results not yet posted but likely moving toward internal analysis and possible future disclosure.
For investors, a completed mid-stage trial in rheumatoid arthritis is a key milestone for Eli Lilly (LLY) and partner Rigel Pharmaceuticals (RIGL), especially in a market dominated by AbbVie, Amgen, and others. If results later show strong efficacy and clean safety, this update can support a stronger pipeline story for LLY and a leveraged upside narrative for RIGL; weak data, however, would likely pressure both stocks once disclosed.
The study has been completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.